WO2004015392A3 - Improved method to identify targeting molecules - Google Patents

Improved method to identify targeting molecules Download PDF

Info

Publication number
WO2004015392A3
WO2004015392A3 PCT/US2003/024994 US0324994W WO2004015392A3 WO 2004015392 A3 WO2004015392 A3 WO 2004015392A3 US 0324994 W US0324994 W US 0324994W WO 2004015392 A3 WO2004015392 A3 WO 2004015392A3
Authority
WO
WIPO (PCT)
Prior art keywords
improved method
kinetic
structure activity
peptides
vivo
Prior art date
Application number
PCT/US2003/024994
Other languages
French (fr)
Other versions
WO2004015392A2 (en
Inventor
Xiao-Min Fan
Elias Lazarides
Catherine Mary Woods
Original Assignee
Targeted Molecules Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targeted Molecules Corp filed Critical Targeted Molecules Corp
Priority to EP03785119A priority Critical patent/EP1542733A2/en
Priority to AU2003264030A priority patent/AU2003264030A1/en
Priority to CA002494551A priority patent/CA2494551A1/en
Publication of WO2004015392A2 publication Critical patent/WO2004015392A2/en
Publication of WO2004015392A3 publication Critical patent/WO2004015392A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Methods for validating the in vivo targeting specificity of compounds according to pharmacokinetic criteria are described. An improved method to generate a library of peptides with reduced complexity and enhanced candidate compound membership comprises expressing oligonucleotides encoding cyclic peptides with randomized coding sequences representing the non-bridging amino acids. Also described is determination of structure activity relationships using kinetic technique using in vivo panning. Design of targeting compounds with appropriate space/charge/hydrophobicity conformations can be based on the results of these kinetic structure activity relationship (kSAR) determinations. In addition, compositions resulting from this methodology are useful in treating neuroinflammatory and lung disorders, and disorders involving disseminated blood cell coagulopathy interactions with vascular endothelium.
PCT/US2003/024994 2002-08-08 2003-08-08 Improved method to identify targeting molecules WO2004015392A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP03785119A EP1542733A2 (en) 2002-08-08 2003-08-08 Improved method to identify targeting molecules
AU2003264030A AU2003264030A1 (en) 2002-08-08 2003-08-08 Improved method to identify targeting molecules
CA002494551A CA2494551A1 (en) 2002-08-08 2003-08-08 Improved method to identify targeting molecules

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US40237202P 2002-08-08 2002-08-08
US60/402,372 2002-08-08
US74092703P 2003-05-14 2003-05-14
US60/740,927 2003-05-14

Publications (2)

Publication Number Publication Date
WO2004015392A2 WO2004015392A2 (en) 2004-02-19
WO2004015392A3 true WO2004015392A3 (en) 2004-07-29

Family

ID=31720595

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/024994 WO2004015392A2 (en) 2002-08-08 2003-08-08 Improved method to identify targeting molecules

Country Status (4)

Country Link
EP (1) EP1542733A2 (en)
AU (1) AU2003264030A1 (en)
CA (1) CA2494551A1 (en)
WO (1) WO2004015392A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004263458B2 (en) * 2003-08-08 2010-06-24 Actgen, Inc. Polypeptides having brain-localizing activity and uses thereof
US20090092583A1 (en) * 2005-08-26 2009-04-09 Makoto Sawada Brain-localizing cells and uses thereof
FR2957597A1 (en) * 2010-03-17 2011-09-23 Univ Picardie SYNTHETIC CYCLOPEPTIDES, PROCESS FOR PREPARATION AND USES
CN108484640B (en) * 2018-05-22 2020-09-15 南京华威医药科技集团有限公司 Anti-tumor apoptosis protein inhibitor
WO2024042466A1 (en) * 2022-08-22 2024-02-29 University Of Tartu Brain penetrating peptides and methods of use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4684621A (en) * 1984-11-21 1987-08-04 Smithkline Beckman Corporation Methods of producing vasodilation or antioxytocic activity
US5622699A (en) * 1995-09-11 1997-04-22 La Jolla Cancer Research Foundation Method of identifying molecules that home to a selected organ in vivo
WO1998010795A2 (en) * 1996-09-10 1998-03-19 The Burnham Institute Tumor homing molecules, conjugates derived therefrom, and methods of using same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4684621A (en) * 1984-11-21 1987-08-04 Smithkline Beckman Corporation Methods of producing vasodilation or antioxytocic activity
US5622699A (en) * 1995-09-11 1997-04-22 La Jolla Cancer Research Foundation Method of identifying molecules that home to a selected organ in vivo
WO1998010795A2 (en) * 1996-09-10 1998-03-19 The Burnham Institute Tumor homing molecules, conjugates derived therefrom, and methods of using same

Also Published As

Publication number Publication date
WO2004015392A2 (en) 2004-02-19
AU2003264030A1 (en) 2004-02-25
CA2494551A1 (en) 2004-02-19
EP1542733A2 (en) 2005-06-22
AU2003264030A8 (en) 2004-02-25

Similar Documents

Publication Publication Date Title
FR17C1062I1 (en)
Pitteri et al. Electron transfer ion/ion reactions in a three-dimensional quadrupole ion trap: reactions of doubly and triply protonated peptides with SO2•
Narjes et al. A designed P1 cysteine mimetic for covalent and non-covalent inhibitors of HCV NS3 protease
Amalian et al. MS/MS digital readout: analysis of binary information encoded in the monomer sequences of poly (triazole amide) s
Tabb et al. Statistical characterization of ion trap tandem mass spectra from doubly charged tryptic peptides
Gidden et al. Duplex formation and the onset of helicity in poly d (CG) n oligonucleotides in a solvent-free environment
GB2366800A (en) Antibody molecules having specificity for human tumor necrosis factor alpha and use thereof
Blumberger et al. Formamide hydrolysis in alkaline aqueous solution: insight from ab initio metadynamics calculations
GB0124317D0 (en) Biological products
WO2004015392A3 (en) Improved method to identify targeting molecules
Hilderbrand et al. Exploring crown ethers as shift reagents for ion mobility spectrometry
WO2008033433A3 (en) Computational music-tempo estimation
Cook et al. Metastable atom-activated dissociation mass spectrometry of phosphorylated and sulfonated peptides in negative ion mode
Newton et al. Gaseous apomyoglobin ion dissociation in a quadrupole ion trap:[M+ 2H] 2+-[M+ 21H] 21+
WO2002018637A3 (en) Diagnosis and treatment of prostate cancer
Park et al. Ab initio studies on the catalytic mechanism of aspartic proteinases: nucleophilic versus general acid/general base mechanism
Chirot et al. Statistical analysis of ion mobility spectrometry. I. Unbiased and guided replica-exchange molecular dynamics
Wendt et al. Quantitative evaluation of noncovalent chorismate mutase-inhibitor binding by ESI-MS
GB0008419D0 (en) A method for invitro molecular evolution of antibody function
Harsch et al. Accurate and rapid modeling of iron–bleomycin-induced DNA damage using tethered duplex oligonucleotides and electrospray ionization ion trap mass spectrometric analysis
WO2005044087A3 (en) Methods for the determination of protein three-dimensional structure employing hydrogen exchange analysis to refine computational structure prediction
van Der Rest et al. Dissociation channel dependence on peptide size observed in electron capture dissociation of tryptic peptides
EP1796707A4 (en) Peptides that selectively home to heart vasculature and related conjugates and methods
TW200516897A (en) Architecture and method of multilayered DRM protection for multimedia service
WO2003006669A3 (en) Efficient methods for assessing and validating candidate protein-based therapeutic molecules encoded by nucleic acid sequences of interest

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2494551

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003785119

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003785119

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWR Wipo information: refused in national office

Ref document number: 2003785119

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2003785119

Country of ref document: EP